Lexeo Therapeutics (NASDAQ:LXEO) Insider Narinder Pal Bhalla Sells 22,306 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the transaction, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO opened at $4.45 on Thursday. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $10.99. The company’s 50-day moving average is $5.12 and its 200 day moving average is $6.63. The company has a market capitalization of $349.41 million, a P/E ratio of -3.07 and a beta of 1.42.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Monday, May 11th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings lowered Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Lexeo Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of LXEO. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares during the last quarter. Bank of America Corp DE lifted its stake in Lexeo Therapeutics by 6.1% in the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares in the last quarter. California State Teachers Retirement System grew its holdings in Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares in the last quarter. Intech Investment Management LLC increased its position in Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after purchasing an additional 2,317 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 25.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock valued at $118,000 after acquiring an additional 2,427 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.